PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
Multicenter, Interventional, Single-arm, Phase IV Study Evaluating Tolerability of Eribulin and Its Relationship With a Set of Polymorphisms in an Unselected Population of Female Patients With Metastatic Breast Cancer
Sponsor: Mario Negri Institute for Pharmacological Research
Listed as NCT02864030, this PHASE4 trial focuses on Adverse Drug Event and Drug Toxicity and remains completed. Sponsored by Mario Negri Institute for Pharmacological Research, it has been updated 9 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Apr 2021 — Jul 2024 [monthly]
Completed PHASE4
Status: Unknown Status → Completed
-
Jan 2021 — Apr 2021 [monthly]
Unknown Status PHASE4
▶ Show 4 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Unknown Status PHASE4
Status: Active Not Recruiting → Unknown Status
-
Sep 2018 — Sep 2020 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE4
First recorded
May 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mario Negri Institute for Pharmacological Research
- Oncologia Medica dell'Ospedale Fatebenefratelli
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bolzano, Italy , Cremona, Italy , Cuneo, Italy , Florence, Italy , Lecce, Italy , Legnano, Italy , Milan, Italy , Pagani, Italy , Pavia, Italy , Piacenza, Italy and 6 more locations